Travere Therapeutics recently reported quarterly results showing higher revenue and a smaller net loss than the prior year, alongside mostly positive Wall Street analyst commentary. At the same time, ...
Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five international databases predicts a substantial, previously underdiagnosed adult NPHS2 ...
Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five ...
In a report released yesterday, Vamil Divan from Guggenheim maintained a Buy rating on Merck & Company, with a price target of $140.00. Claim 55% Off TipRanks. Unlock hedge fund-l ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will ...
Strand Therapeutics, a clinical-stage biotechnology company pioneering programmable mRNA medicines, today announced it will present preclinical data from its in vivo CAR-T program at the 2026 American ...
Johnson & Johnson will present at the Bernstein's 42nd Annual Strategic Decisions Conference on Wednesday, May 27th, 2026.
Pitt Street Research and Euroz Hartleys have released research notes on Dimerix highlighting upside potential as progresses ...
In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Ardelyx, with a price target of $16.00.
An established sales force and payer authorization criteria will fuel a fast launch for Travere Therapeutics’ Filspari in its ...
Travere Therapeutics rated a Buy after Filspari’s FDA approval for FSGS—only therapy available. Read TVTX's valuation upside, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results